Spectrum Pharmaceuticals, Inc v. Sandoz Inc., No. 15-1407 (Fed. Cir. Oct. 2, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Spectrum Pharmaceuticals, Inc. (“Spectrum”) appeals from the decision s of the United States District Court for the District of Nevada holding claims 1–2 of U.S. Patent 6,500,829 (“the ’829 patent”) invalid as obvious , and finding claims 5 –9 of the ’829 patent not infringed by the submission of an Abbreviated New Drug Applica tion (“ANDA”) by Sandoz Inc. (“Sandoz”) . Spectrum Pharm ., Inc. v. Sandoz Inc. , No. 2:12 -cv-00111, 2015 WL 794674 (D. Nev. Feb. 25, 2015) (“ Trial Order”); Spectrum Pharm., Inc. v. Sandoz Inc. , No.